CY1105716T1 - Διαδερμικο εμπλαστρο σταθερο εναντι uv - Google Patents

Διαδερμικο εμπλαστρο σταθερο εναντι uv

Info

Publication number
CY1105716T1
CY1105716T1 CY20061101501T CY061101501T CY1105716T1 CY 1105716 T1 CY1105716 T1 CY 1105716T1 CY 20061101501 T CY20061101501 T CY 20061101501T CY 061101501 T CY061101501 T CY 061101501T CY 1105716 T1 CY1105716 T1 CY 1105716T1
Authority
CY
Cyprus
Prior art keywords
active substance
absorber
matrix
furthest
impermeable
Prior art date
Application number
CY20061101501T
Other languages
English (en)
Inventor
Jochen Schumacher
Manfred Susse
Michael Prof. Dr. Dittgen
Stephan Mletzko
Jan-Peter Ingwersen
Thomas Langguth
Dirk Schenk
Hubert Kaffl
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03003888A external-priority patent/EP1449526A1/de
Priority claimed from EP03004061A external-priority patent/EP1452173A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of CY1105716T1 publication Critical patent/CY1105716T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Abstract

Η εφεύρεση σχετίζεται με νέο διαδερμικό θεραπευτικό σύστημα (TTS), σταθερό έναντι UV, το οποίο αποτελείται από κάποια οπίσθια στιβάδα, τουλάχιστον μία μήτρα περιέχουσα δραστική ουσία και προαιρετικά κάποιο αποσπώμενο φύλλο και περιέχει επιπλέον κάποιον UV-απορροφητή, όπου μεταξύ της οπίσθιας στιβάδας και της πλέον απομακρυσμένης από την επιδερμίδα μήτρας δραστικής ουσίας έχει προβλεφθεί τουλάχιστον μία κολλητική στιβάδα περιέχουσα UV-απορροφητή, και μεταξύ της κολλητικής στιβάδας που περιέχει το UV-απορροφητή και της πλέον απομακρυσμένης από την επιδερμίδα μήτρας δραστικής ουσίας περιέχεται τουλάχιστον μία διαχωριστική στιβάδα η οποία είναι μη διαπερατή στη δραστική ουσία και μη διαπερατή για τον UV-απορροφητή. Το σύμφωνο με την εφεύρεση διαδερμικό θεραπευτικό σύστημα επιτυγχάνει υψηλή σταθερότητα χωρίς τα μειονεκτήματα των συμβατικών TTS που περιέχουν φωτοευαίσθητη δραστική ουσία.
CY20061101501T 2003-02-21 2006-10-19 Διαδερμικο εμπλαστρο σταθερο εναντι uv CY1105716T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03003888A EP1449526A1 (de) 2003-02-21 2003-02-21 UV-stabiles transdermales Pflaster
EP03004061A EP1452173A1 (de) 2003-02-25 2003-02-25 UV-stabiles transdermales Pflaster
PCT/EP2004/001052 WO2004073696A1 (de) 2003-02-21 2004-02-04 Uv-stabiles transdermales pflaster
EP04707912A EP1594483B1 (de) 2003-02-21 2004-02-04 Uv-stabiles transdermales pflaster

Publications (1)

Publication Number Publication Date
CY1105716T1 true CY1105716T1 (el) 2010-12-22

Family

ID=32910125

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101501T CY1105716T1 (el) 2003-02-21 2006-10-19 Διαδερμικο εμπλαστρο σταθερο εναντι uv

Country Status (31)

Country Link
US (3) US8486443B2 (el)
EP (1) EP1594483B1 (el)
JP (1) JP4528296B2 (el)
KR (1) KR100704825B1 (el)
AR (1) AR043248A1 (el)
AT (1) ATE333271T1 (el)
AU (1) AU2004212675B2 (el)
BR (1) BRPI0407615B8 (el)
CA (1) CA2515918C (el)
CR (1) CR7952A (el)
CY (1) CY1105716T1 (el)
DE (1) DE502004000988D1 (el)
DK (1) DK1594483T3 (el)
EA (1) EA008098B1 (el)
EC (1) ECSP056030A (el)
ES (1) ES2270345T3 (el)
HK (1) HK1085394A1 (el)
HR (1) HRP20050828B1 (el)
IL (1) IL170295A (el)
IS (1) IS2541B (el)
ME (2) MEP14008A (el)
MX (1) MXPA05008778A (el)
NO (1) NO336108B1 (el)
NZ (1) NZ541807A (el)
PE (1) PE20041028A1 (el)
PL (1) PL219030B1 (el)
PT (1) PT1594483E (el)
RS (1) RS50428B (el)
SI (1) SI1594483T1 (el)
UY (1) UY28189A1 (el)
WO (1) WO2004073696A1 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL219030B1 (pl) 2003-02-21 2015-03-31 Schering Ag Transdermalny system terapeutyczny w postaci plastra odporny na działanie promieniowania UV
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
WO2006023644A2 (en) * 2004-08-20 2006-03-02 3M Innovative Properties Company Transdermal drug delivery device with translucent protective film
EP1719504A1 (de) * 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
WO2010009122A1 (en) * 2008-07-14 2010-01-21 Surmodics, Inc. Medical devices and methods for delivery of nucleic acids
CN103189064B (zh) * 2010-09-06 2015-08-12 拜耳知识产权有限责任公司 具有高药物释放的低剂量透皮贴剂
DE102010040299A1 (de) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10966936B2 (en) 2015-12-30 2021-04-06 Corium, Inc. Systems comprising a composite backing and methods for long term transdermal administration
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
DE102020104907A1 (de) * 2020-02-25 2021-08-26 Berliner Glas GmbH Verfahren zur Herstellung eines Bauelements durch atomares Diffusionsbonden

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939827A (ja) 1982-08-27 1984-03-05 Nitto Electric Ind Co Ltd 医療用外用部材
JPS6069014A (ja) 1983-09-27 1985-04-19 Nitto Electric Ind Co Ltd 皮膚疾患治療用貼付剤
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
JPS60166611A (ja) 1984-02-10 1985-08-29 Nitto Electric Ind Co Ltd 疾患治療用部材
US5560922A (en) 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
CH674618A5 (el) 1987-04-02 1990-06-29 Ciba Geigy Ag
US5538736A (en) 1987-04-28 1996-07-23 Lts Lohmann Therapie-Systeme Gmbh Active substance-containing plaster for the controlled administration of active substances to the skin
US5128284A (en) 1987-10-23 1992-07-07 Allied-Signal Inc. Preparation of lanthanum chromite powders by sol-gel
EP0370220B1 (de) 1988-10-27 1996-01-10 Schering Aktiengesellschaft Mittel zur transdermalen Applikation enthaltend Gestoden
ES2081458T3 (es) 1990-03-30 1996-03-16 Ciba Geigy Ag Composicion de pintura.
ATE120368T1 (de) 1990-05-17 1995-04-15 Hisamitsu Pharmaceutical Co Estradiol enthaltende transdermale zubereitung.
GB9021674D0 (en) 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
WO1992007590A1 (en) 1990-10-29 1992-05-14 Alza Corporation Transdermal contraceptive formulations, methods and devices
JP3112707B2 (ja) 1991-07-25 2000-11-27 日本電気株式会社 監視システム用ポーリング方式
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4336299A1 (de) * 1993-10-25 1995-05-11 Arbo Robotron Medizin Technolo Gelkörper zur percutanen Verabreichung, insbesondere von Medikamenten
DE4403487C2 (de) * 1994-02-04 2003-10-16 Lohmann Therapie Syst Lts Arznei-Pflaster mit UV-vernetzbaren Acrylat-Copolymeren
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
EP0787488A4 (en) 1994-11-18 1998-06-03 Hisamitsu Pharmaceutical Co TRANSDERMAL ABSORBABLE PLASTER
JP3908795B2 (ja) 1994-11-29 2007-04-25 久光製薬株式会社 ケトチフェン含有経皮投与製剤
PL181582B1 (pl) 1995-06-07 2001-08-31 Ortho Mcneil Pharm Inc Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
JP3626275B2 (ja) 1996-04-09 2005-03-02 Ｊｓｒ株式会社 光硬化性樹脂組成物
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
JP4346696B2 (ja) 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
JP3434135B2 (ja) 1996-07-11 2003-08-04 アルパイン株式会社 ナビゲーション装置
DE19701949A1 (de) 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
JPH10265371A (ja) 1997-03-25 1998-10-06 Sekisui Chem Co Ltd 経皮吸収貼付剤
BR9808594A (pt) 1997-04-16 2000-05-23 Hisamitsu Pharmaceutical Co Composição substrato para absorção percutânea, e, preparação de absorção percutânea.
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
JP4399044B2 (ja) 1998-10-14 2010-01-13 久光製薬株式会社 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤
AU3478200A (en) 1999-02-02 2000-08-25 Ortho-Mcneil Pharmaceutical, Inc. Method of manufacture for transdermal matrices
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DE19912623A1 (de) 1999-03-20 2000-09-28 Lohmann Therapie Syst Lts Verfahren zur Erhöhung der Stabilität bei Lagerung und/oder Anwendung lichtempfindlicher therapeutischer Systeme oder deren Bestandteile
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
EP1197212A4 (en) 1999-07-01 2004-06-02 Hisamitsu Pharmaceutical Co ADHESIVE COMPOSITION FOR PERCUTANE ABSORPTION
JP4841781B2 (ja) 1999-11-24 2011-12-21 アジル・セラピューティクス・インコーポレイテッド 改良された経皮的避妊薬送達系および方法
AU3104301A (en) 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
WO2001068061A1 (fr) 2000-03-17 2001-09-20 Hisamitsu Pharmaceutical Co., Inc. Preparation adhesive protegeant des uv
CA2411950A1 (en) * 2000-06-13 2002-12-09 Hisamitsu Pharmaceutical Co., Inc. Patch
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
US20020106402A1 (en) 2000-12-05 2002-08-08 Hartwig Rod Lawson Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
WO2003077925A1 (en) 2002-03-11 2003-09-25 Janssen Pharmaceutica N.V. Sulfatase inhibiting continuous progestogen contraceptive regimens
US6872401B2 (en) 2002-03-28 2005-03-29 L'oreal Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil
US7470452B1 (en) 2002-06-13 2008-12-30 E. I. Du Pont De Nemours & Company Process for multilayer coating of substrates
US7032980B2 (en) * 2002-06-27 2006-04-25 The Little Tikes Company Non-slip wheel for a child's toy
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
PL219030B1 (pl) 2003-02-21 2015-03-31 Schering Ag Transdermalny system terapeutyczny w postaci plastra odporny na działanie promieniowania UV
EP1452173A1 (de) 2003-02-25 2004-09-01 Schering AG UV-stabiles transdermales Pflaster
US8524272B2 (en) * 2003-08-15 2013-09-03 Mylan Technologies, Inc. Transdermal patch incorporating active agent migration barrier layer
EP1660294B1 (en) 2003-08-25 2008-12-03 BFS Diversified Products, LLC Method and apparatus to monitor the compressive strength of insulation boards
RU2354664C2 (ru) 2003-09-11 2009-05-10 Циба Спешиалти Кемикэлз Холдинг Инк. Концентрированные формы светостабилизаторов на водной основе, полученные по методике гетерофазной полимеризации
US20050129756A1 (en) 2003-12-10 2005-06-16 Hans-Peter Podhaisky UV-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient
UA89766C2 (en) 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
NZ548091A (en) 2003-12-12 2009-12-24 Bayer Schering Pharma Ag Transdermal delivery system of hormones without penetration enhancers
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
JP4504109B2 (ja) 2004-06-15 2010-07-14 株式会社新陽社 画像表示装置及び画素構成体
EP1719504A1 (de) 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
EP2349230A2 (en) 2008-10-06 2011-08-03 Mylan Technologies, Inc. Amorphous rotigotine transdermal system

Also Published As

Publication number Publication date
PL378035A1 (pl) 2006-02-20
MXPA05008778A (es) 2006-05-25
ATE333271T1 (de) 2006-08-15
PT1594483E (pt) 2006-12-29
ECSP056030A (es) 2006-01-27
EA200501224A1 (ru) 2006-04-28
IS8031A (is) 2005-09-15
US20060251707A1 (en) 2006-11-09
NO20054321L (no) 2005-09-20
KR100704825B1 (ko) 2007-04-09
US20130226113A1 (en) 2013-08-29
DK1594483T3 (da) 2006-11-20
US9095691B2 (en) 2015-08-04
IL170295A (en) 2010-05-31
AU2004212675B2 (en) 2006-06-01
HRP20050828A2 (en) 2006-03-31
SI1594483T1 (sl) 2006-12-31
UY28189A1 (es) 2004-04-30
ES2270345T3 (es) 2007-04-01
CA2515918C (en) 2010-11-16
CR7952A (es) 2006-02-06
PE20041028A1 (es) 2005-02-18
JP4528296B2 (ja) 2010-08-18
US8486443B2 (en) 2013-07-16
AR043248A1 (es) 2005-07-20
NO336108B1 (no) 2015-05-18
BRPI0407615A (pt) 2006-02-14
RS20050639A (en) 2007-09-21
IS2541B (is) 2009-09-15
JP2006518348A (ja) 2006-08-10
AU2004212675A1 (en) 2004-09-02
EP1594483A1 (de) 2005-11-16
CA2515918A1 (en) 2004-09-02
NZ541807A (en) 2009-07-31
DE502004000988D1 (de) 2006-08-31
BRPI0407615B1 (pt) 2018-02-14
HK1085394A1 (en) 2006-08-25
BRPI0407615B8 (pt) 2021-05-25
WO2004073696A1 (de) 2004-09-02
RS50428B (sr) 2009-12-31
US20150335658A1 (en) 2015-11-26
EP1594483B1 (de) 2006-07-19
HRP20050828B1 (hr) 2013-10-25
EA008098B1 (ru) 2007-02-27
PL219030B1 (pl) 2015-03-31
KR20050103499A (ko) 2005-10-31
MEP14008A (en) 2010-06-10
ME00147B (me) 2010-10-10

Similar Documents

Publication Publication Date Title
CY1105716T1 (el) Διαδερμικο εμπλαστρο σταθερο εναντι uv
CY1106411T1 (el) Διαδepμικο θepαπευτικο συστημα με fentanyl
CY1106811T1 (el) Διαδερμικη γρανισετρονη
CY1108250T1 (el) Διαδερμικο θεραπευτικο συστημα για τη χορηγηση μη στεροειδικων αντιφλογιστικων που φερουν καρβοξυλομαδες, καθως και μεθοδος για την παραγωγη του
FI6962U1 (fi) Transdermaalinen laastari fentanyylin antamiseksi
CY1109954T1 (el) Διαδερμικο θεραπευτικο συστημα (tts) με τη δραστικη ουσια φεντανυλη
ATE366567T1 (de) Transdermales therapeutisches system mit hochdispersem siliziumdioxid
DK1425035T3 (da) Anvendelse af biologisk aktiv HIV-1 Tat, fragmenter eller derivater deraf til targeting og/eller aktivering af antigen-præsenterende celler og/eller til afgivelse af cargo molekyler til forebyggende eller terapeutisk vaccination og/eller til behandling..
BR0307025A (pt) Ministrador laminado de inseticida, e, uso do mesmo
DK1962815T3 (da) Anvendelse af filmdannende hårplejepolymerer fra gruppen polyurethaner og farmaceutiske tilberedninger og plastre indeholdende nævnte polymerer
DK1313462T3 (da) Anvendelse af asiatisk syre eller asiaticosid til behandling af cancer
DK1706133T3 (da) Fremgangsmåder til beskyttelse mod stråling ved anvendelse af flagellin
IT1319210B1 (it) Pellicola per la somministrazione dermica e transdermica di principiattivi.
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
DE50115451D1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
HUP0204448A2 (en) Trnasdermal therapeutic system for the delivery of lerisetron
CY1115757T1 (el) Στερεο διαδερμικο θεραπευτικο συστημα που περιλαμβανει uv-απορροφητη
DK0825865T3 (da) Transdermalt, terapeutisk system for administrering af testosteron eller testosteronderivat
BR0314300A (pt) Aplicação de substâncias para a proteção da pele
ZA200509384B (en) Method and device for improving the permeability of the human skin
NO992674L (no) Konturen til et transdermalt terapeutisk system
BR0011135A (pt) Sistema de ministração terapêutica transdérmica, processo para ministrar um neuroléptico altamente potente a um indivìduo,e uso de um sistema de ministração terapêutica transdérmica
BR0017046A (pt) Uso de azóis para prevenção de câncer de pele
CU23518A3 (es) Sistema terapéutico transdérmico estable a los rayos ultravioletas